forum.WMHelp.cz

[kirazmattson]

Vriligy 60 mg is not recommended for women because it contains the active ingredient dapoxetine, which is a selective serotonin reuptake inhibitor (SSRI) used to treat premature ejaculation (PE) in men.

Here are the key reasons why Vriligy 60 mg is not recommended for women:

Indication:

Vriligy 60 mg is specifically indicated for the treatment of premature ejaculation in adult men. It is not approved or indicated for use in women.
Mechanism of action:

Dapoxetine, the active ingredient in Vriligy, works by inhibiting the reuptake of serotonin, which helps delay ejaculation in men. This mechanism of action is not relevant or beneficial for women.
Safety and efficacy:

The safety and efficacy of Vriligy 60 mg have not been established in women. Clinical trials and studies have focused on the use of dapoxetine in the male population for the treatment of premature ejaculation.
Potential adverse effects:

The side effects associated with Vriligy 60 mg, such as nausea, dizziness, and headache, may be different or more pronounced in women compared to men.
Lack of regulatory approval:

Vriligy 60 mg, containing the active ingredient dapoxetine, has not been approved by regulatory authorities, such as the FDA, for use in women. It is only approved for the treatment of premature ejaculation in adult men.
It is important to note that using medications intended for a specific gender or condition in a different population can pose significant risks and may not provide the intended therapeutic benefits. Women should consult with their healthcare providers for appropriate treatment options for their specific medical needs.